

**CV – Marianna Cavazza**  
**30<sup>th</sup> January 2021**

<b>PERSONAL DATA</b>	
Name and Surname	Marianna Cavazza
Date and place of birth	Milan, 20th January 1966
Nationality	Italian
Mother tongue	Italian
Known languages	English and French
<b>EDUCATION</b>	
Bachelor of Arts	BA in Political Sciences, majors in economics and history, University of Milan. Dissertation title: Debate on public intervention in the economic system and the Pasquale Saraceno positions [Il dibattito sull'intervento pubblico in Italia e le posizioni di Pasquale Saraceno]. Supervisor: Prof. Pier Luigi Porta. 1991
Master	MSc in Economics, University of York. Dissertation title: The Production of Medical and Health R&D in Social Service: The Case of British NHS. Supervisor: Prof. A.J. Culyer. 1994.
.Doctoral Degree	Doctoral degree in Economics, Catholic University of Milan. Title dissertation: Different models of hospitals' funding and organisation: The impact on resources allocation process [Autonomia economico-finanziaria e organizzazione delle strutture ospedaliere: gli effetti sul processo interno di allocazione delle risorse]. Supervisor: Professor Severino Sterpi and Pier Luigi Porta 1999.
<b>CURRENT PROFESSIONAL POSITION AT SDA</b>	
2012 - 2019	Contracted Research Fellow at the Observatory on Private Healthcare Consumption (Osservatorio sui Consumi Privati in Sanità – OCPS)
2019 - current	Associated Professor of Practice in Government Healthcare Non Profit (GHNP) Division
<b>CURRENT PROFESSIONAL POSITION AT CERGAS</b>	
2009 - current	Research Fellow at Cergas (Centre for Research on Health and Social Care Management) – School of Management, Bocconi University
<b>RESEARCH AREAS</b>	
Research interests	Health policy, private consumption in healthcare, cost analysis
Cost analysis	<ul style="list-style-type: none"> <li>• Evaluating the impact of electronic Logistics Management Information Systems (eLMIS) and electronic Immunization Registries (eIR) in low- and middle-income countries. Bill and Melinda Gates Foundation 2020 – 2022.</li> <li>• The economic value of compassionate use programs. Roche 2020.</li> <li>• Management of patients eligible to PCSK-9 Inhibitors: economic impact and reform proposals [Percorso del paziente che accede al trattamento farmacologico dell'Evolocumab]. Amgen 2019.</li> <li>• Avoided costs estimation for NHS in for profit clinical trials [Stima dei costi evitati con le sperimentazioni cliniche for profit nel SSN]. Academy of Health Care Management and Economics of Novartis. 2017 – 2018.</li> <li>• Medical doctor and patient relationship impact on cost-effect of clinical pathways: The case of adjuvant hormonal therapy in breast cancer [L'impatto della relazione medico-paziente sulla costo-efficacia del percorso di cura]. Giancarlo Quarta Foundation and National Cancer Institute of Milan. 2016 – 2018.</li> <li>• Cost analysis of activity in favour of blood donation by the non-profit organisation AVIS [Analisi dei costi dell'attività di raccolta in sette sedi Avis lombarde]. Avis Lombardia. 2017 – 2018.</li> <li>• Main determinants of health care costs of influenza in high income countries – a systematic review [I costi dell'influenza: revisione sistematica della letteratura e implicazioni per l'Italia]. Angelini. 2016 – 2017</li> <li>• Methodological support in cost analysis aimed at fees definition of ambulatory and prosthesis services [Supporto metodologico nell'analisi dei costi per la determinazione delle tariffe delle prestazioni di specialistica ambulatoriale e di protesica]. Italian Ministry of Health. 2016 – 2017</li> <li>• Cost analysis of blood collection by the non-profit organisation AVIS – Avis Lombardia. 2016 – 2017.</li> <li>• Cost analysis of cardiology implantation procedures. Medtronic, 2015 – 2016</li> <li>• Support creation of pilot network of hospitals related to payment of care for cross border patients – HoNCAB. DG SANCO, European Commission. 2014</li> </ul>

Health policy	<ul style="list-style-type: none"> <li>- 2016.</li> <li>• Cost benchmark in twenty surgical interventions [Benchmark dei costi delle prestazioni sanitarie]. Generali Italia. 2012 – 2013.</li> <li>• Social Economic Burden and Health Related Quality of Life in Patients with Rare Diseases in Europe – BURQoL – RDs. DG SANCO, European Commission, 2011 – 2013</li> <li>• Unit costs of healthcare services in the HTA and economic assessment: which are available information? [Costi unitari delle prestazioni per studi di valutazione economica / HTA: quali le informazioni disponibili]. Italian Medical Devices Producers Association [Assobiomedica], 2010.</li> <li>• Senior advisor to Regione Molise undergoing a recovery plan [Regione Molise: Servizi di Advisory contabile per le regioni sottoposte ai piani di rientro – Edizione 3] 2019 - 2021</li> <li>• The future of the blood system in Italy. Which are the challenges? Which is the next role played by AVIS [Il futuro del sistema trasfusionale in Italia Quali sfide? Quale ruolo per AVIS?] National AVIS, 2019 – 2020.</li> <li>• Policies, organisation and management of clinical trials in Italian hospitals [L'organizzazione dell'attività di sperimentazione clinica]. Academy of Health Care Management and Economics of Novartis. 2015 – 2016.</li> <li>• Non-self-sufficiency assistance in Lombardy: Feasibility of a voluntary funding system [L'assistenza per la non autosufficienza in Lombardia: modelli sui trend presenti e futuri]. CISL Pensionati Lombardia. 2015.</li> <li>• Policies, organisation and management of biomarkers associated with targeted therapies [Politiche, organizzazione e gestione di marcatori biomarker associati a terapie targeted]. CeSBIO – Research Centre on Biotechnologies [Centro Studi sulle Biotecnologie]. 2014 – 2016</li> <li>• The investigation of determinants that impact the diffusion of innovative health technologies. An empirical analysis. European Health Technology Institute – EHTI. 2013 - 2014</li> <li>• The definition of “technological innovation” to identify real innovative medical devices [La definizione di ‘innovazione tecnologica’ per distinguere tra dispositivi medici innovativi e quelli che non contribuiscono a un processo reale di innovazione]. DG Medical Devices, Pharmaceutical Services, Italian Ministry of Health. 2012 – 2013.</li> <li>• Clinical and economic impact of psychological assistance in Piedmont Regional Healthcare [I contributi e l'impatto clinico ed economico dell'assistenza psicologica nel SSR Piemontese]. Piedmont Psychologists Society. 2012.</li> <li>• Plasma collection and hemo-components and hemoderivatives production in Italy [La raccolta di plasma e il sistema di emocomponenti ed emoderivati in Italia]. Members of Hemoderivative Group of Pharma Producers Association [Membri del Gruppo Emoderivati di Farmindustria], 2011–2012.</li> <li>• Clinical trials on medical devices in Italy – 3rd Item: Analysis of pre and post CE marking clinical trials localisation [La sperimentazione clinica dei dispositivi medici in Italia – Obiettivo 3: analisi delle scelte di localizzazione degli investimenti in ricerca clinica pre e post marchio CE]. DG Medical Devices, Pharmaceutical Services, Italian Ministry of Health., 2011 – 2012.</li> <li>• 2020 Vision for Rheumatoid Arthritis Research. Roche, 2011.</li> <li>• Drivers and processes of technologies diffusion in healthcare: The case of DaVinci surgical robot. [Driver e meccanismi di diffusione della tecnologia (e sua innovazione) in sanità: il caso del robot da DaVinci]. AgeN.A.S. e Ministry of Health, 2010-2011.</li> <li>• Organisation and decision making processes in European HTA bodies [Organizzazione e processo decisionale negli istituti di health technology assessment]. Assobiomedica, 2009.</li> </ul>
Private consumption in healthcare	<ul style="list-style-type: none"> <li>• A feasibility and sustainability analysis of a Long Term Fund promoted by a city administration [Un'analisi di fattibilità e di sostenibilità di un fondo sanitario integrativo di tipo A e di natura territoriale nell'ambito della LTC]. Mutua 3 Esse, 2019 – 2020.</li> <li>• Medical tourism in Italy and in Europe. OCPS. 2016 – 2018.</li> <li>• The relationship between private healthcare providers and voluntary healthcare insurance. OCPS 2015 – 2016.</li> <li>• Strategies and proposals for a better positioning of dental office [Strategie e proposte per migliorare il posizionamento competitivo dello studio dentistico]. National Association Italian Dentists [Associazione Nazionale</li> </ul>

<p>Other activities</p>	<p>Dentisti Italiani – ANDI]. 2016.</p> <ul style="list-style-type: none"> <li>• Innovation in voluntary healthcare insurance [Innovazione nell'assicurazione salute]. RBM Salute. 2014 – 2015.</li> <li>• The role of voluntary healthcare insurance in the healthcare prevention activity [Il ruolo della Sanità integrativa nelle attività di prevenzione diretta alla persona]. RBM Salute and Fondo Uni.CA. 2015.</li> <li>• Member of the Research Team of Observatory on Private Consumption in Healthcare [Osservatorio sui Consumi Privati in Sanità – OCPS] since 2012</li> <li>• Collective voluntary insurance bodies. SIVEAS Project, Italian Ministry of Health. 2010-2011.</li> <li>• Observatory on private healthcare in Italy [Osservatorio sull'assistenza sanitaria privata in Italia] – Analysis of Lombardy's Regional Healthcare Fund distribution criteria in favour of private and public providers [Analisi dei criteri di riparto del FSR lombardo confrontando i criteri ex-ante ed ex-post e distinguendo tra soggetti pubblici e privati accreditati]. Assolombarda, 2010.</li> </ul> <p>Since 2014, Coordinator of the drugs and medical devices firms Network associated to Cergas providing update on Italian healthcare system through workshops and strategic support activities.</p>
<p><b>TEACHING ACTIVITY SDA - BOCCONI</b></p>	
<p>Master in Management Sanitario – MiMS 2011 – current</p> <p>Executive Master in Management Sanitario – EMMAS 2015 – 2017 2021</p> <p>Master in International Healthcare Management, Economics and Policy - MIHMEP</p>	<p>Elective course on voluntary healthcare insurance</p>  <p>Tutor on final and field projects on voluntary healthcare insurance</p> <p>Elective course on voluntary healthcare insurance</p>  <p>Course on voluntary healthcare insurance</p>
<p><b>PREVIOUS PROFESSIONAL POSITIONS</b></p>	
<p>Since 17/01/2004 to 31/12/2008</p> <p><i>Main research activity</i></p>           <p>Since 15/10/2001 to 31/12/2004</p> <p><i>Main research activity</i></p>	<p>Contracted Research Fellow at Foundation Cefass – EIPA (European Institute of Public Administration).</p> <ul style="list-style-type: none"> <li>• Mapping Health Services Access: National and Cross-Border Issues. DG SANCO, European Commission, 2005 – 2006.</li> <li>• Relevant training experience on GPs' appropriate prescription of drugs and diagnostic exams [Significative esperienze di formazione sull'appropriatezza delle prescrizioni per i MMG, orientate al buon uso delle risorse, con riferimento alle prestazioni di assistenza farmaceutica, specialistica nonché di diagnostica strumentale]. Age.N.A.S., 2007- 2008.</li> <li>• Training activity on implementation of clinical pathways in primary and secondary care to clinicians, nurses and controllers of Lombardy's Regional Healthcare Service. 2007 – 2008.</li> <li>• Training activity on free movement of patients and healthcare professionals in Europe to public officers of Member States public administrations. 2006 - 2008</li> </ul> <p>Contracted Research Fellow at Regional Health and Social Care Agency of Emilia-Romagna [Agenzia sociosanitaria regionale dell'Emilia-Romagna]</p> <ul style="list-style-type: none"> <li>• Staff of Commission on LTC Fund [Commissione per la realizzazione del progetto speciale "Fondo per la non autosufficienza[. 2003 – 2004.</li> <li>• Economic evaluation on antibiotics' administration models in surgery wards [Valutazione economica dei modelli di preparazione della chemioprolifassi chirurgica nei reparti di chirurgia generale], 2004.</li> <li>• Appropriateness of hospital care payment. Revision of DRG fees through the use of disease staging classification system [L'appropriatezza della remunerazione dell'assistenza ospedaliera. Revisione delle tariffe DRG attraverso l'applicazione del sistema di classificazione del disease staging"] with Thomas Jefferson Medical College of Philadelphia, 2003 – 2004.</li> <li>• Staff of Commission on PPPs experiences in Emilia-Romagna Regional Healthcare Service [Commissione di valutazione delle esperienze di collaborazione pubblico- privato in ambito sanitario in Emilia-Romagna] 2001 – 2002.</li> </ul>

<p>Since 01/09/2000 to 30/09/2001</p> <p><i>Main research activities</i></p> <p>Since 01/04/1999 to 31/08/2000</p>	<p>Contracted Research Fellow Health at the Economic Health Institute [Istituto di Economia sanitaria]</p> <ul style="list-style-type: none"> <li>• Patterns of treatments and costs in mental health departments of Lombardy Region – HoNOS II [Pattern di trattamento e costi nei Dipartimenti di Salute Mentale della Regione Lombardia – Studio HoNOS II". Programma ex. art. 12 l. n. 502/92] 2000 – 2001.</li> </ul> <p>Programme manager in healthcare sector at Cariplo Foundation Fondazione Cariplo. Via Manin 3, Milano</p>
<b>ACADEMIC POSITION</b>	
<p>2017 - current</p> <p>1999 - 2014</p> <p>2004 - 2006</p>	<ul style="list-style-type: none"> <li>• Untenure professor of Healthcare policies at Political Science Faculty, Catholic University of Milan</li> <li>• Untenure professor of healthcare economics at the Medicine School of the University Milano – Bicocca</li> <li>• Untenure professor of healthcare economics at the Public Administration School of the Alma Mater University of Bologna</li> </ul>
<b>PUBLICATIONS</b>	
<p>Chapters of books</p>	<ul style="list-style-type: none"> <li>• M. Cavazza Rossi, The economic culture and teaching in Milan: the students' notes of Bocconi University [La cultura economica milanese e l'insegnamento universitario: le dispense di economia della Università Bocconi]. In P.L. Porta (ed.), Milano e la cultura economica nel XX secolo. I - Gli anni 1890-1920], F. Angeli, 1998.</li> <li>• M. Cavazza, The features of the welfare state: an analysis. [Caratteristiche dello stato sociale: un approfondimento], in CRISP, Cooperative sociali e sviluppo economico in Lombardia, F. Angeli, Milano, 2001.</li> <li>• M. Cavazza, Public policies impact [Le implicazioni di policy], in CRISP, Cooperative sociali e sviluppo economico in Lombardia, F. Angeli, Milano, 2001.</li> <li>• M. Cavazza, Programme agreements in supplying social – healthcare services [Gli accordi di programma e l'integrazione nell'offerta dei servizi socio- sanitari], in G. Fiorentini (ed.) I servizi sanitari in Italia, il Mulino, Bologna. 2002.</li> <li>• M. Cavazza, The economic role of Red Cross organisation [Un'analisi del ruolo di soggetto economico della Croce Rossa Italiana], in C. Cipolla (ed.), Un ricordo della Croce Rossa oggi, Franco Angeli, Milano 2003.</li> <li>• M. Cavazza (ed.), Funding activities of Emilia-Romagna charitable foundations [L'attività di erogazione delle fondazioni di origine bancaria dell'Emilia-Romagna], Maggioli Editore, Rimini, 2004.</li> <li>• C. Bottari – M. Cavazza (ed), Charitable foundations between law and ethics [Le F.O.B. tra normativa ed etica], Bononia University Press, Bologna, 2005.</li> <li>• I. Bosa, A. Carezzi, M. Cavazza, Population ageing and LTC in Europe [L'invecchiamento della popolazione e la LTC in Europa] in II° Rapporto Cefass sul Welfare in Europa (eds by M. Barea, G. Cesana, A. Carezzi), Edizioni scientifiche La Fiorentina, Firenze, 2005.</li> <li>• M. Cavazza et al., Legal and economic aspects of incentives to health workers [Aspetti giuridici ed economici degli incentivi al personale sanitario non medico], Bononia University Press, Bologna, 2006</li> <li>• M. Cavazza, Accessability to healthcare and free movement of patients in Europe [L'accessibilità ai servizi e la libera circolazione dei pazienti in Europa ] in A. Carezzi, G. Cesana, M. Vittadini (eds.) III° Rapporto Cefass sul Welfare in Europa, coordinatori scientifici, MyPrint, Bergamo, 2008.</li> <li>• Cavazza M., Literature review [La rassegna della letteratura]. In Quaderni AGENAS, Significative esperienze di formazione sull'appropriatezza delle prescrizioni per i MMG. Roma 2009.</li> <li>• C. Jommi – M. Cavazza, The decision making process in HTA organisations [Il processo decisionale negli istituti di health technology assessment], in E. Cantù (ed.), Rapporto OASI 2009, EGEA, Milano, 2009.</li> <li>• M. Cavazza - C. De Pietro, Development of collective voluntary healthcare insurance bodies [Sviluppo e prospettive dei fondi integrativi del Servizio Sanitario Nazionale in E. Cantù (ed.) Rapporto OASI 2011, EGEA, Milano, 2011.</li> </ul>

	<ul style="list-style-type: none"> <li>• M. Cavazza – C. De Pietro, Institutional setting and management of seven collective voluntary healthcare insurance bodies [Aspetto istituzionale e scelte di gestione in sei fondi sanitari], in E. Cantù (ed.) Rapporto OASI 2012, EGEA, Milano, 2012.</li> <li>• P. Armeni - C. Cavazza - C. Jommi, Clinical trial activity on medical devices [L'attività sperimentale sui dispositivi medici], in R. Tarricone (ed.) Politiche per la salute e scelte aziendali. Impatto sulla innovazione e diffusione delle tecnologie mediche. EGEA, 2012.</li> <li>• C. Jommi – M. Cavazza, Plasma collection and hemo-components and hemoderivatives production in Italy [La raccolta di plasma e il sistema di emocomponenti ed emoderivati in Italia], EGEA, Milano. 2013.</li> <li>• M. Cavazza – F. Costa – C. Jommi, Clinical trial activity in nine Italian hospitals: Organisation, management and perception analysis [La ricerca clinica in nove ospedali italiani: l'organizzazione ed analisi di percezione], in E. Cantù (ed.), Rapporto OASI 2014, EGEA, Milano 2014.</li> <li>• M. Cavazza, Goals and strategies on funding access to dental care in Italy [Obiettivi e forme d'intervento per finanziare l'accesso alle prestazioni odontoiatriche in Italia]. In C. De Pietro, S. Maggi (eds.), Le prospettive della mutualità nel sistema sanitario italiano. Il Mulino, Bologna 2015.</li> <li>• M. Cavazza, P. Nazzari, C. De Pietro, Dental care: The dental care sector and the collective voluntary healthcare insurance bodies [L'odontoiatria: il settore e i fondi]. In M. Del Vecchio, E. Rappini, V. Rappini (eds.), Rapporto OCPS 2015. Osservatorio sui Consumi Privati in Sanità. EGEA, Milano, 2015.</li> <li>• M. Cavazza, F. Costa, C. Jommi (eds.), Organisation and management of clinical trials [Organizzazione e gestione delle sperimentazioni cliniche]. EGEA, Milano, 2016.</li> <li>• M. Cavazza, M. Del Vecchio, C. De Pietro, V. Rappini, Innovation in voluntary healthcare insurance [L'innovazione nell'assicurazione salute]. EGEA, Milano, 2016.</li> <li>• M. Cavazza, A. Bertolani, C. Jommi. Clinical research in Italy. How much does it worth? [La ricerca clinica in Italia: quanto, come viene finanziata e suoi effetti sul sistema. In G. Gussoni (ed.) The independent clinical research worth in Italy. [Il valore della ricerca clinica indipendente in Italia. Libro Bianco sulla ricerca clinica indipendente: dalle fonti di finanziamento al valore etico e sociale], EDRA, Milano, 2020.</li> <li>• M. Cavazza, How much do cost rare disease? In G. Cenacchi (ed.) Are rare diseases really rare?. 1088press – bits, Bonomia. Under press.</li> </ul>
Articles (peer-reviewed)	<ul style="list-style-type: none"> <li>• M. Cavazza, State and social justice in the experience of Pasquale Saraceno [Stato e giustizia sociale nell'esperienza di Pasquale Saraceno], Società e storia, XV(57), 1992.</li> <li>• M. Cavazza, Sergio Paronetto and Pasquale Saraceno: A matching [Sergio Paronetto e Pasquale Saraceno: un incontro (1936 –1945)]. Economia pubblica, Fasc. 4/5, 1993.</li> <li>• M. Cavazza, P.L. Porta, C. Spagnolo, Parallel biographies: Pasquale Saraceno viewed by Angelo Saraceno [Biografie parallele: Pasquale Saraceno visto da Angelo Saraceno]. Economia pubblica, Fasc. 3, 1994.</li> <li>• G. Antonelli - M. Cavazza, D. Gagliardi, The development of social cooperatives in Lombardy: a survey on potential as well as limits [Lo sviluppo economico delle cooperative sociali in Lombardia: alcuni riscontri empirici su potenzialità e limiti], Nonprofit, n. 4, pp. 477 – 525, 2000.</li> <li>• M. Cavazza Rossi, Social cooperatives and their relationship with public local bodies in Lombardy [Cooperative sociali in Lombardia: I rapporti con gli enti locali], Autonomie locali e Servizi sociali, n. 1, pp. 113 – 117. 2001.</li> <li>• M. Cavazza - G. Civalenti - R. Ravasio, Services and enrolled patients [Servizi e pazienti reclutati]. Epidemiologia e Psichiatria sociale, suppl. n. 4 "Pattern di trattamento e costi nei dipartimenti di salute mentale della Regione Lombardia. Il progetto di ricerca HoNOS II", 2002.</li> <li>• A. Lora - M. Cavazza - V. Mapelli, Diagnosis and severity [Diagnosi e gravità], Epidemiologia e Psichiatria sociale, suppl. n. 4 "Pattern di trattamento e costi nei dipartimenti di salute mentale della Regione Lombardia. Il progetto di ricerca HoNOS II", 2002.</li> <li>• M. Cavazza - M. Fiorini, Evaluation of PPP experiences in Emilia-Romagna healthcare system [Valutazione delle esperienze di collaborazione pubblico-privato nella sanità dell'Emilia-Romagna], Autonomie locali e Servizi sociali, n. 3, pp. 471 – 487. 2002.</li> <li>• M. Cavazza, The contribution of charitable foundations to local communities in Emilia-Romagna [Il contributo delle fondazioni di origine bancaria alle comunità locali: il caso dell'Emilia-Romagna], Nonprofit, n. 2, 2005.</li> </ul>

	<ul style="list-style-type: none"> <li>• C. Jommi - M. Cavazza, HTA organisations and their stakeholders [Istituti di HTA e portatori di interesse], <i>Giornale Italiano di Health Technology Assessment</i>, 2012: Vol, 5, Issue 1, pp 5 – 15.</li> <li>• M. Cavazza – C. Jommi, Stakeholders involvement by HTA Organisations: Why is so different? <i>Health Policy</i>, 2012 Vol. 105, Issue 2, pp. 236-245.</li> <li>• R. Livertovà, P. Serrano – Aguilar et al. and the BURQoL Research Group, Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> 2012 Vol.108, Issue 1, pp.:19-26.</li> <li>• V. Mele – A. Compagni – M. Cavazza, Governing through evidence. A study of technological innovation in healthcare, <i>J Public Adm Res Theory</i> 25th March 2013, doi:10.1093/jopart/mut016.</li> <li>• Y. Kodra - M. Cavazza - A. Schieppati - M. De Santis – P. Armeni – R. Arcieri – G. Calizzani –G. Fattore - L. Manzoli – L. Mantovani – D. Taruscio. The social burden and quality of life of patients with haemophilia in Italy, <i>Blood Transfusion Suppl.</i> 3. 2014.</li> <li>• S. Sommariva, M. Cavazza, A. Compagni, C. Jommi, I registri in sanità e la creazione di conoscenza: dai database alla produzione scientifica, <i>Politiche Sanitarie</i> Vol. 16, N. 3, Luglio-Settembre 2015.</li> <li>• M. Cavazza, Y. Kodra, P. Armeni et al., Social/economic costs and quality of life in patients with haemophilia in Europe, <i>Eur J Health Econ</i> 17(S1) 2016.</li> <li>• M. Cavazza, Y. Kodra, P. Armeni et al., Social/economic costs and quality of life in patients with Duchenne muscular dystrophy in Europe, <i>Eur J Health Econ</i> 17(S1) 2016.</li> <li>• O. Ciani, P. Armeni, P. Boscolo, M. Cavazza, C. Jommi, R. Tarricone, <i>De innovazione: The concept of innovation for medical technologies and its implications for healthcare policy-making.</i> <i>Health Policy and Technology</i>, 5(1) March 2016.</li> <li>• Cavazza M., Fenech L., Lega F., How to develop medical tourism [Sviluppare il turismo sanitario] in "MECOSAN" 99/2016, pp. 125-129, DOI:10.3280/MESA2016-099009</li> <li>• C. Jommi, M.Cavazza, C. Federici. Prioritizzazione dell'offerta vaccinale, accordi di rimborso condizionato e politiche di acquisto sui vaccini. <i>Tendenze Nuove</i> n.1 – 2018; 11-34.</li> <li>• C Federici, M Cavazza, F Costa, C Jommi. Health care costs of influenza-related episodes in high income countries: A systematic review. <i>Health care costs of influenza in high income countries: a systematic review.</i> <i>PLoS One</i> 2018, 13 (9)</li> <li>• C. Jommi, M. Cavazza, Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. <i>Global &amp; Regional Health Technology Assessment</i> Volume 2019: 1–12.</li> <li>• A. Furnari, G. Callea, M. Cavazza, L. Ferrara, F. Lecci, F. Longo, A. Ricci, V. Tozzi, R. Tarricone. Approccio value-based e logiche di finanziamento: implicazioni per le politiche di rimborsabilità in sanità. <i>Mecosan</i> 2019, 112:83-10.</li> <li>• M. Cavazza, H. Banks, M. Muscaritoli, M. Rondanelli, E. Zandonà e C. Jommi, Patient Access to Oral Nutritional Supplements in a Fragmented Health Care System: Are Public Policies Relevant? <i>Nutrition</i> 2020 Jan;69:110560</li> <li>• M. Cavazza, H. Banks, M. Ercolanoni, G. Cukaj, G. Bianchi, G. Capri, F. Longo. Factors influencing adherence to adjuvant endocrine therapy in breast cancer treated women: using real world data to inform a switch from acute to chronic disease management. <i>Breast Cancer Research and Treatment</i> 183, pages189–199(2020)</li> <li>• Y. Kodra, M. Cavazza , M. de Santis, A. Guala, ME Liverani, P.Armeni M. Masini, D. Taruscio. Social Economic Costs, Health-Related Quality of Life and Disability in Patients with Cri Du Chat Syndrome. <i>Int. J. Environ. Res. Public Health</i> 2020, 17, 5951</li> <li>• M. Cavazza, M. Del Vecchio, L. Fenech, L. Giudice, E. Mallarini, L.M. Preti, V. Rappini. Consumi sanitari privati e Covid-19: esperienze e prospettive. <i>Mecosan</i> 2020, 113:165-175.</li> <li>• Armeni, P.; Cavazza, M.; Xoxi, E.; Taruscio, D.; Kodra, Y. Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. <i>Int. J. Environ. Res. Public Health</i> 2021, 18, 1101.</li> </ul>
Conference Papers	<ul style="list-style-type: none"> <li>• Padova, 13rd – 14th October 2000, V Conference of Italian Health Economics Association – AIES. Title: The relationship between clinicians and hospital management [Un'analisi del rapporto tra corpo medico</li> </ul>

	<p>ospedaliero e amministrazione ospedaliera].</p> <ul style="list-style-type: none"> <li>• Bologna, 25th – 27th September 2002, III Conference of Italian Health Economics Association – AIES. The PPP experience in Emilia-Romagna (with M. Fiorini).</li> <li>• Washington D.C. 6 – 10 novembre 2004. 131st Annual Meeting of American Public Health Association – APHA. An Atlas of Appropriateness of Hospital Admissions in the Emilia-Romagna Region, Italy (with D.Z. Louis, A. Donatini, M. Jimbo, J.S. Gonnella, C. Rabinowitz, M. Fiorini, S. Mall, R. Trisolini, E.J. Yuen, V. Maio, F. Taroni).</li> <li>• Bergamo 29th – 30th October 2009, XIV Conference of Italian Health Economics Association – AIES. Technology evaluation: a comparative analysis of decision-making process in the EU countries [La valutazione delle tecnologie. Analisi comparata dei processi decisionali nei principali Paesi UE] (with C. Jommi).</li> <li>• Syracuse 2nd – 4th June 2011. 11th Public Management Research Association Conference. Action, Reaction and Inaction: Governing by Evidence the Diffusion of Technological Innovation in Healthcare (with V. Mele, A. Compagni).</li> <li>• Milano, 25th September 2013, Goals and strategies in dental care access, Conference on Role and Perspective of Mutual Insurance Companies. Fondazione Cesare Fimiv –Pozzo, Cergas-Bocconi, OCPS-SDA Bocconi</li> <li>• Venezia 27th October 2014, XIX Conference of Italian Health Economics Association – AIES. Intermediate costs for non-self sufficiency: The case of Lombardy [Intermediare i costi per la non autosufficienza in ottica mutualistica – Il caso lombardo] (with C. De Pietro, F. Longo, F. Petracca and S. Tasselli).</li> <li>• Milan, 13th – 15th 2017, Annual Conference of the European Health Management Association. Medical tourism in Italy: how public and private hospitals are getting organized (with L. Fenech and F. Lega)</li> <li>• Boston, 7th – 11th July 2017 World International Health Economics Association Conference. A Comparative Study of VHI in Europe: Transformations and Challenges for Public Healthcare System (with M. Del Vecchio and V. Rappini)</li> <li>• Pavia 5th – 6th October 2017, XXII Conference of Italian Health Economics Association – AIES. A comparative analysis of voluntary healthcare insurance in Europe [Uno studio comparato delle assicurazioni sanitarie volontarie in Europa: innovazioni ed evoluzioni nell'ambito dei sistemi sanitari] (with M. Del Vecchio and V. Rappini).</li> <li>• Roma, 12th – 13th October 2017, 10th National Conference of Italian Society of HTA - SIHTA" – Governance aziendale e di sistema. Analisi dei costi delle procedure di impiantistica cardiologica: uno strumento di governo aziendale? (with A. Ricci, G. Callea and R. Tarricone).</li> <li>• Pisa October 3rd-4th October 2019 - XXIV Conference of Italian Health Economics Association – AIES., Health care policy and management after retrenchment: what future for population health? "Stato dell'arte e prospettive del sistema trasfusionale italiano" (with S. Berloto, A. Furnari, E. Ricciuti, G. Briola, P. Colamartino).</li> <li>• de Gennaro, D., Adinolfi, P., Piscopo, G., &amp; Cavazza, M. (2020). "Work Digitalization and Job Crafting: The Role of Attitudes toward Technology"; 17th Italian Chapter of AIS (ItAIS), "Organizing in a digitized world: Diversity, Equality and Inclusion", track: The role of e-HRM and digital innovation in Human Resources Management. Università degli Studi "G. d'Annunzio" Chieti-Pescara (IT), 16–17 ottobre.</li> </ul>
<b>RESEARCH OUTPUTS</b>	
	<ul style="list-style-type: none"> <li>• Research Centre on Healthcare Biotechnologies and Biotech Sector – CESBIO, III Report "Biotech drugs diffusion, policies on biosimilars and cost-effectiveness evidence" [La diffusione dei farmaci biotecnologici, le politiche sui biosimilari e le evidenze di costo-efficacia] 2015.</li> </ul>